As a result of these studies, patients with severe obesity and rare SRC-1 variants are now being recruited into phase 2 clinical trials of setmelanotide, an MC4R agonist, licensed for the chronic weight management of POMC and leptin receptor deficiency (3, 8, 9). The gene discussed is POMC; the disease is obesity due to melanocortin 4 receptor deficiency.